IDEAYA Biosciences Management
Management criteria checks 4/4
IDEAYA Biosciences' CEO is Yujiro Hata, appointed in Jun 2015, has a tenure of 8.83 years. total yearly compensation is $3.33M, comprised of 17.1% salary and 82.9% bonuses, including company stock and options. directly owns 0.91% of the company’s shares, worth $26.52M. The average tenure of the management team and the board of directors is 2.4 years and 5.5 years respectively.
Key information
Yujiro Hata
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 17.1% |
| CEO tenure | 8.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2.4yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?
Feb 22
Ideaya Biosciences: A Strong Bet In Targeted Oncology
Feb 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
Nov 09Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Oct 03IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans
Jul 04We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate
Mar 10Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
Nov 04Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
Oct 06Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering
Sep 14Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials
Aug 29Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%
Aug 25IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M
Aug 15IDEAYA, Amgen in clinical trial deal for small molecule cancer agent
Jul 27Ideaya: Next 6 Months Critical For Precision Oncology Biotech
Jun 16Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week
May 16We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth
Apr 12IDEAYA Biosciences EPS beats by $0.01, misses on revenue
May 10If You Had Bought IDEAYA Biosciences (NASDAQ:IDYA) Shares A Year Ago You'd Have Earned 181% Returns
Mar 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$113m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$74m |
| Mar 31 2023 | n/a | n/a | -US$68m |
| Dec 31 2022 | US$3m | US$570k | -US$59m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$66m |
| Mar 31 2022 | n/a | n/a | -US$55m |
| Dec 31 2021 | US$4m | US$544k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$37m |
| Jun 30 2021 | n/a | n/a | -US$30m |
| Mar 31 2021 | n/a | n/a | -US$31m |
| Dec 31 2020 | US$2m | US$510k | -US$34m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$44m |
| Dec 31 2019 | US$2m | US$457k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$42m |
| Mar 31 2019 | n/a | n/a | -US$38m |
| Dec 31 2018 | US$2m | US$420k | -US$34m |
Compensation vs Market: Yujiro's total compensation ($USD3.33M) is below average for companies of similar size in the US market ($USD6.57M).
Compensation vs Earnings: Yujiro's compensation has been consistent with company performance over the past year.
CEO
Yujiro Hata (49 yo)
8.8yrs
Tenure
US$3,327,004
Compensation
Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.8yrs | US$3.33m | 0.91% $ 26.5m | |
| Chief Scientific Officer | 2.4yrs | US$1.49m | 0% $ 0 | |
| Chief Medical Officer | 1.4yrs | US$2.53m | 0.043% $ 1.3m | |
| Principal Accounting Officer | 3.3yrs | no data | 0.033% $ 959.8k | |
| Chief Technology Officer | 1.3yrs | no data | no data | |
| Chief Legal Officer & Company Secretary | 4.5yrs | US$1.16m | 0.013% $ 391.2k | |
| Chief of Staff & Clinical Development | 2.1yrs | no data | no data |
2.4yrs
Average Tenure
51yo
Average Age
Experienced Management: IDYA's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.8yrs | US$3.33m | 0.91% $ 26.5m | |
| Independent Director | 4.3yrs | US$150.45k | 0% $ 0 | |
| Independent Director | 8.5yrs | US$155.45k | 0.0057% $ 167.5k | |
| Independent Director | 3.2yrs | US$141.95k | 0% $ 0 | |
| Chair of Scientific Advisory Board | 5.2yrs | no data | no data | |
| Independent Director | 5.8yrs | US$156.95k | 0% $ 0 | |
| Independent Director | 2yrs | US$224.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 5.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Independent Chairman of the Board | 8.3yrs | US$142.95k | 0.022% $ 639.5k | |
| Independent Director | 3.8yrs | US$141.95k | 0% $ 0 |
5.5yrs
Average Tenure
66.5yo
Average Age
Experienced Board: IDYA's board of directors are considered experienced (5.5 years average tenure).